JP2024506940A5 - - Google Patents

Info

Publication number
JP2024506940A5
JP2024506940A5 JP2023549820A JP2023549820A JP2024506940A5 JP 2024506940 A5 JP2024506940 A5 JP 2024506940A5 JP 2023549820 A JP2023549820 A JP 2023549820A JP 2023549820 A JP2023549820 A JP 2023549820A JP 2024506940 A5 JP2024506940 A5 JP 2024506940A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
composition according
amino acid
acid sequence
chain variable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023549820A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024506940A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/016841 external-priority patent/WO2022178159A1/en
Publication of JP2024506940A publication Critical patent/JP2024506940A/ja
Publication of JP2024506940A5 publication Critical patent/JP2024506940A5/ja
Pending legal-status Critical Current

Links

JP2023549820A 2021-02-18 2022-02-17 Tnf様リガンド1a(tl1a)に対するヒト化抗体を含む組成物及びその使用 Pending JP2024506940A (ja)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US202163150825P 2021-02-18 2021-02-18
US63/150,825 2021-02-18
US202163180892P 2021-04-28 2021-04-28
US63/180,892 2021-04-28
US202163226037P 2021-07-27 2021-07-27
US63/226,037 2021-07-27
US202163285781P 2021-12-03 2021-12-03
US63/285,781 2021-12-03
PCT/US2022/016841 WO2022178159A1 (en) 2021-02-18 2022-02-17 Compositions comprising humanized antibodies to tnf-like ligand 1a (tl1a) and uses thereof

Publications (2)

Publication Number Publication Date
JP2024506940A JP2024506940A (ja) 2024-02-15
JP2024506940A5 true JP2024506940A5 (cg-RX-API-DMAC7.html) 2025-02-25

Family

ID=82931032

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023549820A Pending JP2024506940A (ja) 2021-02-18 2022-02-17 Tnf様リガンド1a(tl1a)に対するヒト化抗体を含む組成物及びその使用

Country Status (19)

Country Link
US (1) US20240309104A1 (cg-RX-API-DMAC7.html)
EP (1) EP4294444A4 (cg-RX-API-DMAC7.html)
JP (1) JP2024506940A (cg-RX-API-DMAC7.html)
KR (1) KR20230157973A (cg-RX-API-DMAC7.html)
AU (1) AU2022223420A1 (cg-RX-API-DMAC7.html)
BR (1) BR112023016672A2 (cg-RX-API-DMAC7.html)
CA (1) CA3207817A1 (cg-RX-API-DMAC7.html)
CL (1) CL2023002424A1 (cg-RX-API-DMAC7.html)
CO (1) CO2023011969A2 (cg-RX-API-DMAC7.html)
CR (1) CR20230436A (cg-RX-API-DMAC7.html)
DO (1) DOP2023000162A (cg-RX-API-DMAC7.html)
EC (1) ECSP23070237A (cg-RX-API-DMAC7.html)
GE (2) GEAP202416596A (cg-RX-API-DMAC7.html)
IL (1) IL305312A (cg-RX-API-DMAC7.html)
JO (1) JOP20230185A1 (cg-RX-API-DMAC7.html)
MX (1) MX2023009622A (cg-RX-API-DMAC7.html)
PE (1) PE20231681A1 (cg-RX-API-DMAC7.html)
TW (1) TW202246322A (cg-RX-API-DMAC7.html)
WO (1) WO2022178159A1 (cg-RX-API-DMAC7.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20240122922A (ko) 2013-03-27 2024-08-13 세다르스-신나이 메디칼 센터 Tl1a 기능 및 관련된 신호전달 경로의 저해에 의한 섬유증 및 염증의 완화 및 반전
TWI703158B (zh) 2015-09-18 2020-09-01 美商希佛隆公司 特異性結合tl1a之抗體
EP3969621A4 (en) 2019-05-14 2023-01-25 Prometheus Biosciences, Inc. TL1A PATIENT SELECTION METHODS, SYSTEMS AND DEVICES
TW202600603A (zh) 2019-10-24 2026-01-01 美商普羅米修斯生物科學股份有限公司 針對類-tnf配體1a (tl1a)之人類化抗體及其用途
US20260216326A1 (en) * 2022-12-22 2026-07-30 Prometheus Biosciences, Inc. Methods of treating inflammatory diseases with combination of tl1a inhibitors and s1pr inhibitors
EP4665767A2 (en) * 2023-02-17 2025-12-24 Prometheus Biosciences, Inc. Anti-tl1a antibody compositions and methods of treatment in the bile duct
IL325993A (en) 2023-08-11 2026-03-01 Paragon Therapeutics Inc TL1A binding proteins and methods of use
US12473370B2 (en) 2023-10-03 2025-11-18 Absci Corporation TL1A associated antibody compositions and methods of use

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3375B1 (ar) * 2010-11-08 2019-03-13 Regeneron Pharma أجسام مضادة بشرية للجين a1 الشبيه بعامل النخر الورمي (tl1a)
UY35148A (es) * 2012-11-21 2014-05-30 Amgen Inc Immunoglobulinas heterodiméricas
CN105814081B (zh) * 2013-11-13 2021-02-02 辉瑞大药厂 肿瘤坏死因子样配体1a特异性抗体及其组合物和用途
US10968279B2 (en) * 2016-05-09 2021-04-06 Bristol-Myers Squibb Company TL1A antibodies and uses thereof
MY191324A (en) * 2016-10-26 2022-06-15 Cedars Sinai Medical Center Neutralizing anti-tl1a monoclonal antibodies
CN119735681A (zh) * 2018-04-25 2025-04-01 普罗米修斯生物科学公司 优化的抗tl1a抗体
TW202600603A (zh) * 2019-10-24 2026-01-01 美商普羅米修斯生物科學股份有限公司 針對類-tnf配體1a (tl1a)之人類化抗體及其用途

Similar Documents

Publication Publication Date Title
JP2024508762A5 (cg-RX-API-DMAC7.html)
JP2024016177A5 (cg-RX-API-DMAC7.html)
KR102289394B1 (ko) 인간 프로그램화된 사멸 수용체 pd-1에 대한 항체의 안정한 제제 및 관련된 치료
JP2020518599A5 (cg-RX-API-DMAC7.html)
JP2022532927A5 (cg-RX-API-DMAC7.html)
JP2016534052A5 (cg-RX-API-DMAC7.html)
JP2021512881A5 (cg-RX-API-DMAC7.html)
JP2020518600A5 (cg-RX-API-DMAC7.html)
JP2020509031A5 (cg-RX-API-DMAC7.html)
JP2021524231A5 (cg-RX-API-DMAC7.html)
JP2024544523A5 (cg-RX-API-DMAC7.html)
JP2025032102A5 (cg-RX-API-DMAC7.html)
JP2024531151A5 (cg-RX-API-DMAC7.html)
JP2024540377A5 (cg-RX-API-DMAC7.html)
JP2023540025A5 (cg-RX-API-DMAC7.html)
US20190010224A1 (en) Formulations of engineered anti-il-10 antibodies
JP2023537316A5 (cg-RX-API-DMAC7.html)
AR124067A2 (es) Formulaciones estables que comprenden un anticuerpo biespecífico para egfr / c-met
JP2023504748A5 (cg-RX-API-DMAC7.html)
JP2024538140A5 (cg-RX-API-DMAC7.html)
RU2018129077A (ru) Стабильная фармацевтическая композиция
US20250019421A1 (en) Pharmaceutical formulation comprising bispecific antibody against rabies virus g protein and preparation method therefor
CL2024000232A1 (es) Composición farmacéutica de anticuerpo anti-pd-1 y uso de la misma
JP2025165988A (ja) プラスミノーゲンとの結合のための抗体
JP2009529915A5 (cg-RX-API-DMAC7.html)